A carregar...

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother
Main Authors: Royal, Richard E., Levy, Catherine, Turner, Keli, Mathur, Aarti, Hughes, Marybeth, Kammula, Udai S., Sherry, Richard M., Topalian, Suzanne L., Yang, James C., Lowy, Israel, Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322622/
https://ncbi.nlm.nih.gov/pubmed/20842054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181eec14c
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!